Patents by Inventor Philip Lienau

Philip Lienau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9884849
    Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: February 6, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Dirk Kosemund, Ulrich Lücking, Gerhard Siemeister, Arne Scholz, Philip Lienau
  • Patent number: 9884063
    Abstract: The present invention relates to amido-substituted azole compounds of general formula (I), in which X1, X2, R1, R2, R4, R5, R7 and R8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: February 6, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Knut Eis, Jens Ackerstaff, Sarah Wagner, Daniel Basting, Stefan Golz, Eckhard Bender, Volkhart Min-Jian Li, Philip Lienau, Ningshu Liu, Franziska Siegel, Marcus Bauser, Detlev Sülzle, Simon Holton, Michaela Bairlein, Philipp Buchgraber, József Bálint
  • Publication number: 20180028507
    Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients, in which: R1 represents a group selected from: C1-C3-alkoxy-C2-C3-alkyl-, (A), (B), (C), (D), (E), (F), (G) or (H); wherein * indicates the point of attachment to the rest of the molecule; R2 represents a group selected from: (I), (J) or (K); wherein * indicates the point of attachment to the rest of the molecule.
    Type: Application
    Filed: February 16, 2016
    Publication date: February 1, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES
  • Patent number: 9877954
    Abstract: The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: January 30, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich Lücking, Niels Böhnke, Arne Scholz, Philip Lienau, Gerhard Siemeister, Ulf Bömer, Dirk Kosemund, Rolf Bohlmann, Ludwig Zorn
  • Publication number: 20180022750
    Abstract: The present invention relates to 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl-substituted imidazopyridazine compounds of general formula (I) in which R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 21, 2015
    Publication date: January 25, 2018
    Inventors: Knut EIS, Ingo HARTUNG, Kirstin PETERSEN, Philip LIENAU, Ulf BÖMER
  • Publication number: 20180016272
    Abstract: Compound of formula (I), processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: January 25, 2016
    Publication date: January 18, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Volker SCHULZE, Gerhard SIEMEISTER, Philip LIENAU, René TEMPEL, Jozsef BÁLINT
  • Patent number: 9856242
    Abstract: The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: January 2, 2018
    Assignee: Bayer Pharma Aktiengesellscaft
    Inventors: Dirk Kosemund, Ulrich Lücking, Arne Scholz, Gerhard Siemeister, Philip Lienau
  • Publication number: 20170342064
    Abstract: The present invention relates to prodrug derivatives of Mps-1 kinase inhibitors, and their use for the treatment and/or prophylaxis of diseases.
    Type: Application
    Filed: December 7, 2015
    Publication date: November 30, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Volker SCHULZE, Hans-Georg LERCHEN, Ulrich LÜCKING, Antje Margret WENGNER, Gerhard SIEMEISTER, Philip LIENAU, Ursula KRENZ
  • Patent number: 9790189
    Abstract: The present invention relates to 5-fluoro pyrimidine derivatives containing a sulfondiimine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: October 17, 2017
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich Lücking, Arne Scholz, Philip Lienau, Gerhard Siemeister, Rolf Bohlmann, Ulf Bömer
  • Patent number: 9783543
    Abstract: The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: October 10, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ludwig Zorn, Knut Eis, Volker Schulze, Detlev Sülzle, Florian Puehler, Philip Lienau, Ulf Bömer, Kirstin Petersen, Andrea Hägebarth
  • Patent number: 9777004
    Abstract: The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: October 3, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Knut Eis, Florian Puehler, Ludwig Zorn, Volker Schulze, Detlev Sülzle, Philip Lienau, Andrea Hägebarth, Kirstin Petersen, Ulf Bömer
  • Publication number: 20170260198
    Abstract: Compounds of formula (1) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: February 21, 2017
    Publication date: September 14, 2017
    Applicants: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Marion HITCHCOCK, Anne MENGEL, Vera PÜTTER, Gerhard SIEMEISTER, Antje Margret WENGNER, Hans BRIEM, Knut EIS, Volker SCHULZE, Amaury Ernesto FERNANDEZ-MONTALVAN, Stefan PRECHTL, Simon HOLTON, Jörg FANGHÄNEL, Philip LIENAU, Cornelia PREUSSE, Mark Jean GNOTH
  • Patent number: 9745304
    Abstract: The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: August 29, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ludwig Zorn, Knut Eis, Volker Schulze, Detlev Sülzle, Florian Puehler, Philip Lienau, Ulf Bömer, Kirstin Petersen, Andrea Hägebarth
  • Patent number: 9730929
    Abstract: The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: August 15, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr
  • Publication number: 20170226092
    Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyperproliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). R2 represents the group (a).
    Type: Application
    Filed: October 13, 2015
    Publication date: August 10, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Dirk KOSEMUND, Ulrich LÜCKING, Gerhard SIEMEISTER, Arne SCHOLZ, Philip LIENAU
  • Publication number: 20170216304
    Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 3, 2015
    Publication date: August 3, 2017
    Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
  • Publication number: 20170217938
    Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: October 14, 2015
    Publication date: August 3, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Dirk KOSEMUND, Ulrich LÜCKING, Gerhard SIEMEISTER, Arne SCHOLZ, Philip LIENAU
  • Publication number: 20170217949
    Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Ulrich LÜCKING, Rolf BOHLMANN, Arne SCHOLZ, Gerhard SIEMEISTER, Mark Jean GNOTH, Ulf BÖMER, Dirk KOSEMUND, Philip LIENAU, Gerd RÜHTER, Carsten SCHULTZ-FADEMRECHT
  • Publication number: 20170202815
    Abstract: The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: April 3, 2017
    Publication date: July 20, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich LÜCKING, Niels BÖHNKE, Arne SCHOLZ, Philip LIENAU, Gerhard SIEMEISTER, Ulf BÖMER, Dirk KOSEMUND, Rolf BOHLMANN, Ludwig ZORN
  • Patent number: 9708293
    Abstract: The present invention relates to N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: July 18, 2017
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich Lücking, Niels Böhnke, Arne Scholz, Philip Lienau, Gerhard Siemeister, Ulf Bömer, Dirk Kosemund, Rolf Bohlmann, Ludwig Zorn